Life Sciences · NYSE: A
Agilent earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends October · next results expected around 23 Nov 2026
Latest: Q3 FY2026
Agilent's new 9500 ICP-MS and flagship GCs launched to orders above plan, while early pharma reshoring orders from five of the top 10 pharma companies back a multi-year instrument cycle.
Demand strengthened across Agilent's largest end markets. Pharma grew 12%, helped by biotech spending, GLP-1 testing and nearly 30% growth in the specialty CDMO business. China returned to growth after a flat expectation, with wins at two leading CXOs and in PFAS testing. Launches from the June ASMS conference are ahead of plan. These include the 9500 ICP-MS, the 8890B and 8860B GCs and the Altura column family. Instrument orders have met or exceeded revenue for ten straight quarters, and the BioCare acquisition added antibody menu to pathology.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 FY24 | $1.7B * |
| Q1 FY25 | $1.7B |
| Q2 FY25 | $1.7B |
| Q3 FY25 | $1.7B |
| Q4 FY25 | $1.9B * |
| Q1 FY26 | $1.8B |
| Q2 FY26 | $1.8B |
| Q3 FY26 | $1.9B |
Data
| Q1 FY25 | $1.11 |
| Q2 FY25 | $0.75 |
| Q3 FY25 | $1.18 |
| Q1 FY26 | $1.07 |
| Q2 FY26 | $1.20 |
| Q3 FY26 | $1.28 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 FY24 | 24.0% |
| Q1 FY25 | 22.4% |
| Q2 FY25 | 18.0% |
| Q3 FY25 | 20.7% |
| Q4 FY25 | 23.8% |
| Q1 FY26 | 19.6% |
| Q2 FY26 | 21.7% |
| Q3 FY26 | 23.6% |
Data
| Q4 FY24 | $388.0M |
| Q1 FY25 | $334.0M |
| Q2 FY25 | $107.0M |
| Q3 FY25 | $259.0M |
| Q4 FY25 | $452.0M |
| Q1 FY26 | $175.0M |
| Q2 FY26 | $201.0M |
| Q3 FY26 | $439.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7Bd | $1.7B | $1.7B | $1.7B | $1.9Bd | $1.8B | $1.8B | $1.9B |
| Operating income | $408.0Md | $376.0M | $300.0M | $360.0M | $443.0Md | $353.0M | $399.0M | $444.0M |
| Operating margin | 24.0% | 22.4% | 18.0% | 20.7% | 23.8% | 19.6% | 21.7% | 23.6% |
| Net income | $351.0Md | $318.0M | $215.0M | $336.0M | $434.0Md | $305.0M | $339.0M | $362.0M |
| Diluted EPS | — | $1.11 | $0.75 | $1.18 | — | $1.07 | $1.20 | $1.28 |
| Operating cash flow | $481.0Md | $431.0M | $221.0Md | $362.0Md | $545.0Md | $268.0M | $277.0Md | $519.0Md |
| Capital expenditure | $93.0Md | $97.0M | $114.0Md | $103.0Md | $93.0Md | $93.0M | $76.0Md | $80.0Md |
| Free cash flow | $388.0M | $334.0M | $107.0M | $259.0M | $452.0M | $175.0M | $201.0M | $439.0M |
| R&D expense | $111.0Md | $113.0M | $112.0M | $111.0M | $119.0Md | $117.0M | $126.0M | $123.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 1 Sep 202610-Q for the period ended 31 Jul 2026SEC ↗
- 1 Jun 202610-Q for the period ended 30 Apr 2026SEC ↗
- 3 Mar 202610-Q for the period ended 31 Jan 2026SEC ↗
- 22 Dec 202510-K for the period ended 31 Oct 2025SEC ↗
- 29 Aug 202510-Q for the period ended 31 Jul 2025SEC ↗
- 2 Jun 202510-Q for the period ended 30 Apr 2025SEC ↗
- 3 Mar 202510-Q for the period ended 31 Jan 2025SEC ↗
- 20 Dec 202410-K for the period ended 31 Oct 2024SEC ↗